Surfactante en Falla Respiratoria Aguda ¿Es una alternativa?

1 Palle R. Propedies, function, and origin of the alveolar lining layer. Nature.1955;175:1125-6.

2 Macklin C. The pulmonary alveolar mucold and pneurnocycles. Lancet 1954: 1099-104.

3 Fujiwara T, Maeta H, Chida S, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet. 1980;1:55-9.

4 Halliday H. Natural vs Synthetic surfactants in neonatal respirstory distress syndrome. Drugs. 1996;51 226-37.

5 Merrit T, Hallman M, Spragg R, Heldt G, Gilliard N. Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome. Drugs.1989;38:591-611.

6 Horbar J, Wright L, Soil R. For the National Institute of Child Health and Human Development Neonatal Research Network, A multicenter randomized trial comparing two surfactants for the treatments of neonatal respiratory distress syndrome. J Pedialt 1993;23:757-66.

7 Jobe A. Pulmonary surfactants therapy. N Engl J Med:1993;328:861-8.

8 Kattwinkel J, Bloom B, Delmore D. Prophylactic administration al calf lung surfactant extrac more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weigh gestation. Pediatrics. 1993;92:90-8.

9 Greene K,Wrigh J, Steinberg K. Serial changes in surfactant associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Date Med 1999;160:1843-50

10 Merrit T, Hallman M, Bloom B. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med.1986;315:785-90.

11 Hoekstra R,JacksonJ, MyersT. I mproved neonata' su rvival following multiple doses of bovino surlaolant In very prematuro neonates at risk for respiratory diarreas syndrome.Pediairics.1991;88:10.8.

12 Soll Hoekstra R, Fangman J. Multicenter trial of dose modified bovine surfactant extract(Survanta) for prevention of respiratory distress syndrome. Pediatrics, 1990;85:1092-102.

13 Goertner L. Bernsau Pohlandt F. Early treatment of respiratory distress syndrome with bovina surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatr Pulmonol. 1992;14:4-9.

14 Liechty E, Donovan E, Purohit D. Reduction of neonatal mortality after muIple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991;88;19.28.

15 Corbel A, Bucciarelli R, Goldman S. Decresead mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant a multicenter controlled trial J. Pediatr.1991;118:277.84.

16 Long W, Thompson T, Sundell H. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without broncopulmonary dysplasia in 700 to 1.350 g infants with respiratory distress syndrome. J Pediatr. 1991;118:595-605.

17 The OSIRIS Collaborative Group. Early versus delayed neonatal administration of synthetic surfactant The judgment of OSIRIS. Lancel.1992;340:1363-9.

18 Lee K, Khoshnood B, Wall S. Trend in mortality from respiratory distress syndrome in the United States 1970-1995. J Pediatr. 1999;134:434.40.

19 Sehgal S, Ewing C, RichardsT. Modified bovine surfactant (Survanta) versus a protein free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants, a pilot study. Natl Med. Assoc. 1994;84:46-52.

20 Vermont Oxfort Trials Network. A multicenter randomized trial comparing synthetic surfactant modified vs bovine Surfactant in the treatment of neonatal respiratory distress syndrome. Pediatr Res 1994;35:259.40. (Abstract)

21 Grauaug A, Kohan R, Milner G. Pulmonary function changes using Exosurf or Survanta-randomized trial. Pediatr Res.1995;37:333 (Abstract).

22. Hudak M, Matteson E, Baus J. Infasurf V. Exosurf for the treatment of RDS: a ten center ramdomized double-masked comparison trial. Pediatr Res.1994;35:231.

23 Egan E, Notter R, kwong M, Shapiro D. Natural and artificial lung surfactant replacement therap in premature lambs. J Appi Physiol.1983;55:875.83.

24 Cummings J, Holm E, Hudak N. A controlled clinical comparison of four different surfactar preparations in surfactant deficient preterm lambs. J Am Rev Respir Dis 1992;145:999-1004.

25 Rooney S. The surfactant system and lung phospholipid biochemistry. Am Res Respir Dis, 1985;131:439-60.

26 Hawgood S. Surfactant: Composition. Structure, and Metabolism. ln: Crystal R, Weel B. editors. The Lung, Scientific Foundation. 2da. Ed. Philadelphia: Lippincott. Raven Publishers. Philadelphia.1997.p.560-4

27 White R, Damm D, Miller J. Isolation and characterization of the human pulmonary surfactant apoprotein gene. Nature.19685;317:361-3.

28 Whitsett J. Ohning B, Ross G. Hydrophobic surfactant associated protein in whole lung surfactant and its importance for biophysical activity in lung surfactant extracts used for replacement therapy. Pediatr Res. 1986;20:460-7

29 Johanson J, Cursted T. Molecular structures and interaction of pulmonary surfactant components, Eur J Biochem.1997;244:0675-93.

30 Wright J, Clemente J. Metabolism and turnover al lung surfactant Am Rev RespirDis. 1987;135:426-44.

31 Harris J, Jackson F, Moxley M, Longmore W. Effect of exogenous surfactant instillation experimental acute lung injury. J Appl Physiol. 1989;66:1846-51.

32 Richman P. Spragg R. Merritt T. Administration of porcine lung surfactant lo humans w ARDS: initial experience. Am Rev Respir Dis.1987,135:A5.

33 NosakaS, Sakai T. Yonekura K. Surfactant for adult with respiratory failure. Lancet. 1990;336:947-8.

34 Spragg R, Gilliard N, Richman P. Acute effects of a single dose of porcine surfactant on patter with acute respiratory distress syndrome. Chest. 1995;105:195-202.

35 Holm B, Matalon S. Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome. Anesth Anal. 989;69:805-18.

36 Petty T, Silvers G, Paul G, Stanford R. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome Chest.1979;75:571-4.

37 Crouch E, Persson A, Chang D, Heuser J. Molecular structure of pulmonary surfactant protein D (SP-D). JBiolChem.1994;269:17311.17319.

38 Poulain F. Alien L., Williams M, Hammiltion R. Hawgood S. Effects of surfactant apolipoproteins on liposome structure: Implications for tubular myelin formation, Am J Physiol.1992;262:L730.L739.

39 Hawgood S, Shiffer K. Structures and properties of surfactant -associated proteins. Annu Rev Physiol.1991;53:375.94.

40 Suzuki Y, FujitaY, Kogishi K. Reconstitution of tubular myelin from Synthetic lipids and proteins associated with pig pulmonary Surfactant. Am Rev Respir Dis.1989;140:75.91.

41 Kuroki Y, Mason R. Voefker D. Pulmonary surfactant apoprotein A structure and modulation of surfactant secretion by rat alveolar type II cells. J Biol Chern.1988:263:3388-94.

42. Gregory T, Longrnore W, Moxley M. Surfactant chemical composition and biophysical acclivity in acute respiratory distress syndrome. J Clin Invest.1991;65:1976-81.

43 Pison U, Obertacke U, Brand M. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma.1990;30:19-26.

44 Hallman M, Spragg R, Harrell J, Moser K, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest.1982;70:673-83.

45 Pison L. Seeger W, Buchhorn R. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis.1989;140:1033-9.

46 Young S, Crapo J, Kremers S, Brumley G. Pulmonary surfactant lipid production in oxygen exposed rat lungs. Lab Invest.1982,46:570-6.

47 Holm B, Notter K, Siegle J, Matalon S. Pulmonary physiological and surfactant changes during injury and recovery from hyperoxia. J App Physiol.1985;59:1402-9.

48 Ashbaugh D, Bigelow D, Petty T, Levine B. Acute respiratory distress syndrome in adults. Lance1.1967;2:319-23.

49 Petty T. Reiss O, Paul G. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis.1977;115:531-6.

50 Lewis J, Jobe A. Surfactant and the Adult Respiratory Distress Syndrome. Am Rev Respir Dis. 1993;147:218-33.

51 Weg J, Reines H, Balk R: Safety and efficacy of an aerosolized surfactant in human sepsis induced ARDS. Chest. 1991;100:137

52 Aldamiz-Echevarría L, Rodríguez J, Arana J, Emparanza J, Izquierdo M, Landa J. Presentación de un lactante afecto de distrés respiratorio tipo adulto y tratado con surfactante pulmonar. An Esp Pediatr.1994;40:311-2

53 Moreno M, López-Herce J, Merello C, Alcaraz A, Carrillo A. Exogenous surfactant therapy for acute respiratory distress in infancy. Intensive Care Med.1996;22:87

54 LeVine A, Lotze A, Stanley S. Surfactant content in children with inflammatory lung disease. Crit Care Med 1996;24:1062-7.

55 Weidemann H, Baughman R, deBoisblanc B. A multi-centered trial in human sepsis induced ARDS of an aerosolized synthetic surfactant. Am Rev Respir Dis. 1992;45:A1-84.

56 Willson D, Jiao J, Bauman L. Zaritsky A. Calf’s lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med.1996;24:1316-22.

57 Walmralh D, Gunter A. Ghofrani H. Bronchoscopic surfactant administration in patients with severe acute respiratory distress syndrome and Sepsis. Am J Respir Crit Care Med.1996;154:157-9.

58 Wilison D, Bauman L, Zaritsky A. Instillation of calf’s lung surfactant extract (Infasurt) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med. 1999; 27:188.95

59 Simon V. Exogenous Surfactant Replacement in ARDS. NEJM.2004;351:853-5.

60 Wyncoll D. Evans T. Acute respiratory distress syndrome. Lancet.1999;354:497-501.

61 Chung Ming C, Chia-Lang F, Chien His C. Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury. Crit Careo Med.2001;29(11):2169-75.

62 Gregory T, Steinberg K, Spragg R, Gadek J, Hyers T. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am, J. Respir. Crit. Care Med. 1997;155(4):1309- 15.

63 Piva T, Cox P, Chatrkaw P. Ventilación de alta frecuencia por oscilación comparado con ventilación mecánica convencional asociada a reposición de surfactante en conejos – J Pediatr (Rio J.).2000;76:349-56.

64 Kerr M, Paton J. Surfactant Protein Levels in Severe Respiratory Syncytial Virus Infection Am. J. Respir. Crit. Care Med.1999;159:1115-8.

65 Luchetti M , Ferrero F , Gallini C. Multicenter randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Ped Crit Care Med.2002;3(3):261-8.

66 Shane T. Exogenous Surfactant Suplementation en Infants with Respiratory Syncitial Virus Bronchiolilis Am J Respir Crit Care. 2000;162(4)1251-6

67 Spragg R,. Lewis J. Effect of Recombinant Surfactant Protein C-Based Surfactant on the Acute Respiratory Distress Syndrome N Engl J Med.2004;351:884-92.

68 Willson D, Thomas N; Markovitz B; Bauman L: DiCario J. Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung injury: A Randomized Controlled Trial for the Pediatric Acute Lung Injury and Sepsis Investigators. JAMA 2005;293:470-6.